An observational study in Recurrent Implantation Failure and Infertility (IVF Patients), sponsored by King's College London. Not yet recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by King's College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Infertility with a site in United Kingdom — 5 open to participants now, 6 under way, none of them phase 3. Infertility · United Kingdom.
Among the 48 studies in Infertility with a site in United Kingdom, this one is the 12th largest by planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2026, is one of 19 observational ones, and was the 48th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →5 of the 48 studies in Infertility with a site in United Kingdom are open now. Recruiting first, the newest first:
Conceivable Life Sciences · Sites in United Kingdom
Ages 18–38
Cardiff University · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18–60 · Healthy volunteers
Genie Fertility Ltd · Sites in United Kingdom
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 8 · Phase 4 7
First in 1999; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 200 across 592 observational studies indexed under Infertility.
Median enrollment 247 across the 29 interventional studies, 100 across the 19 observational. Of the 32 that completed or were terminated, 11 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 48 have an industry lead sponsor. The 10 most frequent:
King's College London is the lead sponsor of 522 studies on the registry; 128 are open to participants now.
King's College London has 3 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
1 of the studies in Infertility with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02081924Imperial College LondonReproductive Hormones During Sustained Administration of Kisspeptin | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 48 studies in Infertility with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn whether differences in the immune cells of the womb lining (endometrium) help explain why some women do not become pregnant despite several IVF attempts using good-quality embryos, a condition known as recurrent implantation failure (RIF). The study compares women with RIF to women who have had a natural, healthy pregnancy. The main question it aims to answer is:
Do immune cells in the endometrium, including uterine natural killer cells, macrophages, B cells, and T cells, differ in number or function between women with RIF and fertile controls?
Researchers will compare endometrial tissue and blood samples from the RIF group to samples from the fertile control group to see whether specific immune cell patterns are linked to implantation failure, and whether these differences could point to future treatment targets.
Participants will:
Recurrent implantation failure (RIF) is a phenomenon specific to assisted reproductive technology, defined using the ESHRE threshold where the calculated cumulative chance of pregnancy exceeds 60 percent yet pregnancy does not occur without a known cause. True incidence is estimated at around 5 percent. While embryonic factors affecting implantation have been substantially addressed through developments such as preimplantation genetic testing for aneuploidy (PGT-A), there remains a lack of robust research into the uterine environment itself, hampered by inconsistent definitions and investigations without established evidence of benefit.
The immune system is known to mediate implantation by balancing pro-inflammatory and anti-inflammatory activity, both to permit implantation and to avoid rejection of the embryo. This study characterises the local, tissue-resident immune cell populations of the endometrium, examining not only the number of each immune cell type present but also their phenotype and function, using surface protein expression, transcriptomic profiling, and T cell receptor sequencing to assess activation state, functional subtype, and clonal expansion within each population.
Recruitment: RIF participants are identified at King's Fertility through internal database searches and clinical record review. Control participants who have had a spontaneous pregnancy are identified through review of 36 week gestation scan appointments at the Harris Birthright Centre, King's College Hospital, between 12 and 36 months prior. Eligible individuals are approached by a member of their direct care team by email and invited to a consent appointment, which can take place remotely.
Study procedure: The mid-luteal phase is identified using twice daily home urinary ovulation prediction tests from day 9 of the menstrual cycle. Participants attend a study visit 7 days after the luteinising hormone (LH) surge, where transvaginal ultrasound and venepuncture are used to confirm a corpus luteum and serum progesterone level consistent with the mid-luteal phase. An endometrial biopsy is then performed at the same visit under transabdominal ultrasound guidance. Where a participant consents to optional future use of samples, an additional blood sample of up to 18ml is collected on the same day, bringing total blood volume to up to 25ml where this option is taken. All procedures take place at King's Fertility, First Floor, The Fetal Medicine Research Institute, 16 to 20 Windsor Walk, Denmark Hill, London SE5 8BB.
Sample processing and analysis: Endometrial tissue and blood samples are transported to the King's College London Immunoregulation Laboratory, Guy's Campus, where endometrial biopsies are immediately cryopreserved and blood is processed to isolate cells from plasma before cryopreservation. Conventional flow cytometry and fluorescence activated cell sorting (FACS) are used for cell sorting and characterisation. CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by sequencing) allows simultaneous analysis of transcriptomic and surface protein expression profiles. Single cell RNA sequencing on the 10x Genomics platform, including T cell receptor (TCR) sequencing, is performed to assess immune cell phenotype and clonal expansion. Raw sequencing data are processed using CellRanger and analysed in Seurat (R environment), producing transcriptomic profile, surface protein expression, and TCR repertoire data. Differential expression and clonality analyses compare immune cell phenotypes between the RIF and control groups, integrating gene expression, surface phenotype, and lineage.
Translational aim: This work is intended to build a high resolution reference atlas of the non-receptive endometrium, allowing stratification of individuals affected by RIF according to underlying immune aetiology, and to identify immune cells or pathways that could inform future immune modulating therapeutic approaches, whether through upregulation or downregulation of a specific immune pathway.
Women under 40 with recurrent implantation failure following IVF, identified through clinical records at King's Fertility (Denmark Hill and Harley Street), and women with a history of spontaneous pregnancy resulting in live birth, identified through 36-week gestation scan records at the Harris Birthright Centre, King's College Hospital. Both groups are drawn from patients already attending these services, approached by their direct care team if they have previously consented to research contact.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Recurrent Implantation Failure (RIF) Cohort:
Control Cohort:
Exclusion Criteria:
Recurrent Implantation Failure (RIF) Cohort:
Control Cohort (in addition to all RIF cohort exclusions above):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women meeting the ESHRE definition of recurrent implantation failure (failure to achieve pregnancy despite an estimated cumulative chance of implantation exceeding 60%), with unexplained infertility, recruited through King's Fertility.
Women with a history of at least one spontaneous pregnancy resulting in live birth, at least 12 months postpartum, with no history of subfertility, recruited through the Harris Birthright Centre, King's College Hospital.
Th17/Treg ratio in the endometrium
Ratio of T helper 17 (Th17) cells to regulatory T (Treg) cells in endometrial tissue, measured by flow cytometry and single-cell RNA sequencing/CITE-seq, compared between participants with recurrent implantation failure (RIF) and fertile controls.
Time frame: Through study completion, up to 27 months
Reference atlas of endometrial immune cell populations
High-resolution profiling of endometrial-resident immune cell populations, including uterine natural killer cells, macrophages, B cells, and T cells, by single-cell RNA sequencing and CITE-seq, to identify transcriptomic and phenotypic patterns associated with implantation failure.
Time frame: Through study completion, up to 27 months
Candidate immune targets for future therapeutic research
Identification of immune cell populations, activation states, or clonal T-cell expansions that covary with the Th17/Treg axis and may represent candidate targets for future therapeutic research in recurrent implantation failure.
Time frame: Through study completion, up to 27 months
Plan to share: Yes — Pseudonymised individual participant data, including transcriptomic, proteomic, and T cell receptor sequencing data, may be deposited in a controlled-access repository and/or shared directly with other researchers upon reasonable request, subject to approval by the Chief Investigator, as data custodian, and King's College London's research governance office, and a formal data sharing agreement. Given the genomic nature of the data, full anonymisation is not possible; re-identification is only possible via a secure linkage key held by designated, authorised members of the research team. Processed or summary-level data not carrying re-identification risk may be made available more openly, for example as supplementary material accompanying publications.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Data and supporting documents will become available following publication of the primary study results, anticipated after study completion (currently estimated June 2029). Data will remain available for the duration of the study's approved archiving period, 25 years from study completion, in line with the protocol's archiving policy, after which the linkage key will be destroyed and data anonymised.
Access criteria: Access is available to researchers with a legitimate scientific proposal for further ethically approved research, upon written request to the Chief Investigator. Requestors will be required to sign a formal data sharing agreement and, where applicable, obtain approval from King's College London's research governance office. Raw sequencing data will be accessed via a controlled-access repository. Processed or summary-level data may be provided directly. Access is limited to pseudonymised data, re-identification is not possible without the secure linkage key held by the research team.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.